Fine Motor Kinematics in In Vivo Pharmacology
Supported by:
1 December 2016
Impairment of fine motor skills is used as an early diagnosis marker in muscular degenerative and neurodegenerative diseases. Scientists at Charles River use a novel automated and high-precision system, the MotoRater, to successfully analyze early changes in muscular or neuronal function in disease models to support the development of therapeutics that reverse or slow progressive degeneration and to test compounds that can cause fine motor impairment as a side effect.
KEYNOTE SPEAKERS
- Taneli Heikkinen, PhD, Senior Scientist, Team Leader, Charles River
- Timo Bragge, MSc, Principal Data Scientist, Charles River
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Drug Development, Neurosciences, Pharmacology
Related organisations
Charles River Laboratories
